Dotz Nano Limited · ASX:DTZ
Dotz Nano — Investor Presentation (June 2022)
29 slides from Dotz Nano's investor presentation, Jun 15, 2022
Slide 1: Protecting people, brands, and the environment with Graphene and Carbon Dots
For personal use only JUNE 2022* Protecting people, brands, and the environment with Graphene and Carbon Dots * Pursuant to ASX Listing Rule 15.5, Dotz confirms that this Presentation has been authorised for release to ASX by the board of directors of Dotz ("Board"). 1
Slide 2: What are Graphene Quantum Dots?
For personal use only Non-toxic Carbon Adjustable Technology. Made from carbon sources, Graphene Quantum Dots The fluorescence colour can be tuned by changing the What are Graphene (GQDs) are a non-toxic size, chemistry, or doping - advanced material creating unique optical Quantum Dots? fingerprint
Slide 3: Business domains
Business domains. For personal use only BIO Product Authentication Diagnostics & Empowering Industries and Traceability Bio-Imaging In / on product tagging technology In product tagging & RT-LAMP In-field material management & Carbon technology Capture technologies 3
Slide 4: The opportunity
The opportunity.* For personal use only $509B $100B+ $4B SHIELD Product Authenticity & Traceability Global Counterfeit Goods (1) Global Anti-Counterfeiting Global Market for Anti- Technologies Market (2) Counterfeiting Packaging (3) $18B $328M $689M $5B BIO Global Rapid Medical Zika Virus Testing Gl
Slide 5: SHIELD Product Authenticity & Traceability
For personal use only SHIELD Product Authenticity & Traceability 5
Slide 6: SHIELD Advanced Security Markers
SHIELD Advanced Security Markers For personal use only Our large portfolio of markers can be seamlessly imbedded into plastics, fuels, lubricants, chemicals, and even Cannabis plants, allowing traceability of raw materials, transparency of supply chain, authentication and anti-delusion. End to End S
Slide 7: The challenge
SHIELD For personal use only The challenge. Pharmaceuticals Safety & health +$3Tr (1) Tobacco Industrial products Counterfeiting Market • Stricter environmental and social +3.3% of World Trade(2) regulations • Increased losses due to Industrial fluids counterfeiting and parallel markets • Product ow
Slide 8: What we do
SHIELD In-Product On-Product For personal use only What we do. Polymers Liquids Lubricants Tax Stamps Printing on Packaging Labels Cement Aiming to disrupt authentication, track and trace, anti tampering and anti alteration by Detectors, Scanners & Connecting the physical to DOTZ Mobile App the digi
Slide 9: Solution benefits
SHIELD Solution benefits. For personal use only Secured Robust Easy-to-Operate Difficult to reverse- Does not affect product Intuitive user interface, engineer properties requiring minimal training Durable Customizable Comprehensive Proprietary markers, Multi-layered solution, All-in-one, advanced w
Slide 10: Competitive environment
SHIELD Competitive environment. For personal use only Price vs. Security - on-product tagging High Price* - in-product tagging DNA XRF Low High NFC Security RFID Holograms Security Inks Low 10
Slide 11: Pipeline. Business Model.
SHIELD For personal use only Pipeline. Business Model. We are currently in advanced stages of communication • Our Solution includes 3 layers and technical valuation with leading players in these industries*: In-product/ Detector/ Cloud • Textile & fashion – traceability of supply chain on-product Ap
Slide 12: SHIELD Product roadmap
SHIELD Product roadmap. Development Under Exploring future For personal use only Completed Development development* Broader Enhanced UV & Enhanced spectral GQDs/CDs temp. stability spectral coding responses Taggants Color / Detection of Fluorescence Spectrum broader spectral detection detection resp
Slide 13: BIO Diagnostics and bio-imaging
BIO For personal use only Diagnostics and bio-imaging. 13
Slide 14: Rapid Detection; Gene Therapy & Bio-Processing
BIO BIO For personal use only Rapid Detection Dotz completes development, testing and CE registration of Dotz Test Kits, an RT-LAMP-based solution, which fast-tracks results for SARS- CoV-2 detection. The company plans to adapt this technology to other viruses and applications. Gene Therapy & Bio-Pr
Slide 15: The solution
BIO The solution. For personal use only viruses Current Gold Vs BIO Standard PCR RT-LAMP Collection By medical staff Saliva/Swab Incubation RNA Extraction RNA Purification Isothermal Amplification Incubation Visual Results Detection Result Analysis ~30 Min* Hours 15 * Validation in clinical trials.
Slide 16: Diagnostics key-points
BIO BIO For personal use only Diagnostics key-points. Saliva Based or European CE certified Rapid results in 30 minutes2 Oropharyngeal swab rapid of both saliva and field test oropharyngeal test kits1 RNA based method in Cost-effective and low 97% Specificity & 100% contrast to Antigen based operati
Slide 17: Possible Future Diagnostic Assays
BIO COVID-19 ZIKA For personal use only Possible Future InfluenzaA Diagnostic Assays*. Agriculture Denguefever Lassavirus 17 * This slide represents future areas the company would like to explore. The company has yet to make any progress is development of such solutions
Slide 18: BioDotz Applications
BIO BIO For personal use only BioDotz™ Applications. BioDotz™ are Dotz tracers utilized for bio-imaging, biosensors, drug delivery, and medical diagnosis. Recently, Dotz signs agreement with global biotech company to utilize its BioDotz ™ for Gene and Cell Therapies (GCTs) processing. Specifically,
Slide 19: Traceability with Dotz during GCTs processing
Traceability with Dotz during GCTs processing. For personal use only 19
Slide 20: ENHANCE Empowering industries
ENHANCE For personal use only Empowering industries 20
Slide 21: In-field dosage management; CO2 Capture and Reduction
ENHANCE For personal use only In-field dosage management Over the last 3 years Dotz has developed and validated in small-scale pilot a solution for the in-field detection of corrosion inhibitor concentrations for the oil & gas industry. Plans to expand the pilot in the next few weeks. CO2 Capture an
Slide 22: FY21 main achievements
FY21 main achievements For personal use only Successful field Technology Successful capital pilots innovation raise Dotz completed several successful Dotz completed development of During 2021 Dotz successfully pilots performed in labs as well as multiple advanced materials as well completed fundrais
Slide 23: Key priorities for FY 22/23
Key priorities for FY 22/23 For personal use only • New and experienced management team to build structure, processes and procedures • Shifting focus to product, commercialization and sales: o Advanced negotiations currently underway with multiple potential customers (however there is no certainty t
Slide 24: Why invest in Dotz?
Why invest in Dotz? For personal use only Promising Huge and growing Unique technology commercialization markets & knowhow prospects • Innovative technology & cost- • Innovative and patented1 versatile • The new contract with Theracell sign effective solution for growing technology with unique featu
Slide 25: Financials
Financials. For personal use only • As of 31 March 2022, Dotz had a cash and equivalents balance of US$2.785 million (31 December 2021: US$4.137 million). o 29% - R&D o 11% - Marketing o 60% - Operation and Administration 25
Slide 26: Risks
Risks. COVID-19 Latent impacts For personal use only Events related to COVID-19 still have resulted in significant market volatility. There is continuing uncertainty as to the ongoing and future impact of COVID-19 including in relation to the nature, timing and duration of the responses of governmen
Slide 27: Experienced Company Leadership
Experienced Company Leadership For personal use only Bernie Brookes Doron Eldar Michael Shtein, Ph.D., MBA Chairman Executive Director CTO Mr Brookes is an experienced Australian executive, CEO and Doron Eldar is a result-focused entrepreneur with more than a Dr. Shtein holds a Ph.D. in Nano technol
Slide 28: Thank you
For personal use only Thank you. 28
Slide 29: Disclaimer
Disclaimer • This presentation has been prepared by Dotz Nano Limited (Dotz). It does not purport to contain all the information that a prospective investor may require in connection with any potential For personal use only investment in Dotz. You should not treat the contents of this presentation,